Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.79 |
| ▸ | NPC1 | O15118 | 7/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | RORC | P51449 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31349930 | 1.00 | SMN1; SMN2 (0.79) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL7838823 | 0.92 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL7838822 | 0.92 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL6814385 | 0.90 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL30577265 | 0.86 | SMN1; SMN2 (0.81) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL1083471 | 0.86 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| Hydrochloric Acid SCHEMBL11158946 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL11158941 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| Fluoride SCHEMBL11790867 | 0.85 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9AHPGDHTT | |
| SCHEMBL405569 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1HTTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113999130-A | Preparation method of o-nitroanilide compound | 湖北工业大学 | 2022-02-01 | — | — | CN | claimed |
| CN-109232544-B | Preparation method of prucalopride | 江苏工程职业技术学院 | 2021-09-14 | — | — | CN | claimed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-113999130-B | Preparation method of o-nitroanilide compound | 湖北工业大学 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023154183-A1 | COMPOSITION INCLUDING EFFERVESCENT AGENTS, BIOSTIMULANT, NUTRIENT, AND PESTICIDE | ROBBINS JEFFREY (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-4171744-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTAIN OCULAR DISORDERS | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-4172146-A1 | SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY | Bayer Aktiengesellschaft (DE) | 2023-05-03 | — | — | EP | disclosed |
| EP-3296735-B1 | SEPARATING AGENT FOR OPTICAL ISOMERS | DAICEL CORP (JP) | 2022-02-16 | — | — | EP | disclosed |
| CN-113999130-A | Preparation method of o-nitroanilide compound | 湖北工业大学 | 2022-02-01 | — | — | CN | disclosed |
| CN-109232544-B | Preparation method of prucalopride | 江苏工程职业技术学院 | 2021-09-14 | — | — | CN | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
| WO-1999067222-A1 | METHODS OF INHIBITING CORROSION USING ISOMERS OF CHLORO-METHYLBENZOTRIAZOLE | BETZDEARBORN INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5968408-A | ODORLESS | BETZDEARBORN INC. (US) | 1999-10-19 | — | — | US | disclosed |
| CN-1183277-A | Vasopressin antagonist and oxytocin antagonist | OTASUKA PHARMACEUTICAL CO LTD (JP) | 1998-06-03 | — | — | CN | disclosed |
| CN-1098716-A | Vasopressin antagonists and oxytocin antagonists | OTSUKA CHEMICAL CO LTD (JP) | 1995-02-15 | — | — | CN | disclosed |
| CN-1004204-B | Herbicide containing triazine derivative as active ingredient | 出光兴产株式会社 | 1989-05-17 | — | — | CN | disclosed |
| CN-86100884-A | Process for preparing triazine derivatives and herbicides containing the derivatives as active ingredient | — | 1986-08-13 | — | — | CN | disclosed |
| US-4600797-A | NITRATING AN AMINOBENZENE WHICH HAS A PROTECTEDD AMINO GROUP | BAYER AKTIENGESELLSCHAFT (DE) | 1986-07-15 | — | — | US | disclosed |
| EP-0049711-B1 | PROCESS FOR THE PRODUCTION OF NITRO-AMINO-BENZENES | BAYER AG (DE) | 1984-02-29 | — | — | EP | disclosed |
| EP-0049711-A1 | Process for the production of nitro-amino-benzenes | BAYER AG (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | SMN1; SMN2 2827/4885NPC1 1905/4885RAB9A 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.